Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662571 · ClinicalTrials.gov registry record
Acamprosate: Genes Associated With Response
A clinical trial of Alcoholism, sponsored by Mayo Clinic.
- Completed
- Registry status
- 485
- Enrollment target
- 1
- Study location
NCT00662571: Completed study of Alcoholism, sponsored by Mayo Clinic.
NCT00662571 is a study of Alcoholism that has completed, run by Mayo Clinic. The registered enrollment target is 485 participants, above the 368-participant average among 65 other Alcoholism trials with a reported enrollment target (32% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00662571, a study of Alcoholism, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 485 participants
- Enrollment target
- 1
- Study location
Study Summary
In 2004, acamprosate was approved in the U.S. for abstinence maintenance, by decreasing craving, in alcoholic patients who have undergone detoxification. while a new anti-craving drug was encouraging, only 36.1% of the subjects treated with acamprosate remained abstinent for 6 months. Having the ability to identify treatment responsive individuals would have a major impact on the use of acamprosate.
Conditions Studied
Interventions
- DRUG acamprosate
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 485 participants |
| Start Date | 2008-05 |
| Est. Completion | 2013-02 |
What the finished NCT00662571 record still lists
NCT00662571 is an observational study that tracks outcomes without assigning an intervention. The registered 485 participants enrollment target is mid-sized for trials with a published cap, above the 368-participant average among 65 other Alcoholism trials with a reported enrollment target (32% higher).
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 1 intervention - of which acamprosate is the first listed.
NCT00662571 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00662571 about?
NCT00662571 is a clinical study titled "Acamprosate: Genes Associated With Response". In 2004, acamprosate was approved in the U.S. for abstinence maintenance, by decreasing craving, in alcoholic patients who have undergone detoxification. while a new anti-craving drug was encouraging, only 36.1% of the subjects treated with acamprosate remained abstinent for 6 months. Having the abi...
What is the current status of trial NCT00662571?
This trial is currently completed. The enrollment target is 485 participants. The study started on 2008-05. Estimated completion is 2013-02.
What conditions does trial NCT00662571 study?
This clinical trial studies the following conditions: Alcoholism.
What interventions are being tested in trial NCT00662571?
The interventions under investigation include: acamprosate (DRUG).
Who is sponsoring clinical trial NCT00662571?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00662571 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00662571's enrollment target sits among peer trials
485 8th of 65 higher than 58 of 65 other Alcoholism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcoholism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Naltrexone in AUD Reward Drinkers
RECRUITING · Phase 4
-
Characterization Imaging Instruments in Alcoholics and Non-Alcoholics
RECRUITING
-
Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder
RECRUITING · NA
-
Alcohol and the Social Brain: an Alcohol-Administration Hyperscanning Study
RECRUITING
-
Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment of Alcohol Use Disorder (AUD)
RECRUITING · NA
-
CRP and S&A for Inpatient Veterans
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07124910 · 485 participants · Phase 3
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
- NCT06420531 · 486 participants · NA
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
- NCT07097142 · 486 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- NCT05421741 · 484 participants · Phase 4
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia